NCT04264000

Platelet-rich Plasma Injection for Ulnar Neuropathy at Elbow

Platelet-rich Plasma Injection for Ulnar Neuropathy at Elbow: A Randomized Double-blind Trial

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 30 (actual)
• Sponsor: Yung-Tsan Wu · Academic / Other
• Sex: All
• Age: 20 Years – 80 Years
• Healthy volunteers: Accepted

Summary

Ulnar neuropathy at elbow (UNE) is the second common peripheral entrapment neuropathy after carpal tunnel syndrome (CTS). Although many conservative managements of UNE were found, their effectiveness were often unsatisfied without existed guideline. Recently, the perineural injection of 5% dextrose wate (D5W) is a novel management for CTS but its effect for UNE is not obviously as CTS. Hence, it is very important to find another novel injectate for UNE.

Detailed description

The platelet-rich plasma (PRP) is a new and potential treatment for patients with kinds of musculoskeletal disorders and recent reports showed being beneficial for peripheral neuropathy in animal studies. Our previous research shown single injection with PRP was superior to D5W for CTS. However there is no study investigating the effect of PRP for UNE now. Hence, the purpose of this study was to assess the effect of perineural PRP injection for UNE.

Conditions

• Ulnar Neuropathy at Elbow

Interventions

Type	Name	Description
DRUG	platelet-rich plasma	Ultrasound-guided 3cc PRP injection between medial epicondyle and ulnar nerve
DRUG	5% dextrose	Ultrasound-guided 3cc 5% dextrose injection between medial epicondyle and ulnar nerve

Timeline

• Start date: 2020-08-01
• Primary completion: 2024-03-31
• Completion: 2024-03-31
• First posted: 2020-02-11
• Last updated: 2024-04-10

Locations

1 site across 1 country: Taiwan